Eli Lilly Stock: Next Stop $2,000? The company is riding an incredible tailwind.
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
Is Kailera Therapeutics a Buy After Its Sizzling IPO? There's a new challenger to the more established players in the weight-loss drug space.
Buy, Sell, or Hold Novo Nordisk at $46? Can Novo Nordisk thrive under intense competitive pressures?
My Top 3 Healthcare Stocks for May 2026 Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook Amphastar Pharmaceuticals (
NASDAQ:AMPH ) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
Bill Peters, chief financial officer of Amphastar
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Eli Lilly (LLY) Stock Trades Up, Here Is Why What Happened? Shares of global pharmaceutical company Eli Lilly (
NYSE:LLY ) jumped 2.4% in the afternoon session after the stock continued to rally as the co...
Why Hims & Hers Health Stock Just Crashed Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity.
The 3 Best S&P 500 Stocks to Buy Now These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.
